Hematologic Oncology | Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2020 ASH Annual Meeting - a podcast by Dr Neil Love
from 2021-02-12T19:15
::
::
Featuring an interview with Dr Aaron T Gerds on the following topics:
- Biologic rationale for the use of JAK inhibitors; key data supporting the FDA approval of ruxolitinib and fedratinib for myeloproliferative neoplasms (MPN) (0:00)
- Real-world survival among patients with intermediate- to high-risk myelofibrosis (MF) in the United States: Impact of ruxolitinib approval (3:09)
- Effect of ruxolitinib for inadequately controlled polycythemia vera (PV) without splenomegaly: Five-year results from the Phase III RESPONSE-2 study (5:27)
- Long-term safety of fedratinib for patients with intermediate- or high-risk MF (8:31)
- Activity and tolerability of momelotinib in patients with MF (11:37)
- Choice of JAK inhibitor for patients with MF (15:38)
- Risks and benefits with fedratinib for patients with MF who experience disease progression on ruxolitinib (23:05)
- Clinical experience with fedratinib in the treatment of MF (26:12)
- Improvement in survival outcomes, symptoms and quality of life with JAK inhibitors (34:33)
- Activity and tolerability of the telomerase inhibitor imetelstat in patients with intermediate 2- or high-risk MF that is relapsed or refractory to JAK inhibitors (39:16)
- Navitoclax with ruxolitinib in different populations of patients at high risk with relapsed/refractory MF (46:35)
- Role of ruxolitinib in therapy for patients with essential thrombocythemia and PV; effect of the hepcidin mimetic PTG-300 on treatment for PV (55:14)
- Efficacy of eprenetapopt (APR-246), a small molecule reactivator of mutant and inactivated p53, for myelodysplastic syndromes (MDS) with TP53 mutation (59:44)
- Hypomethylating agents in combination with venetoclax for elderly patients with acute myeloid leukemia (AML) (1:01:43)
- Benefits and risks of CPX-351 for patients with AML (1:08:21)
- Ongoing investigation of the oral combination of decitabine and cedazuridine for AML (1:10:30)
- Perspective on CC-486 (oral azacitidine) as maintenance therapy for patients with AML (1:13:08)
- Role of luspatercept for the treatment of anemia associated with MDS (1:16:01)
CME information and select publications
Further episodes of Research To Practice | Oncology Videos
Further podcasts by Dr Neil Love
Website of Dr Neil Love